Omnipod® 5 Trainers & Educators
Product Highlights
Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system in the US market.
- Indicated for type 1 diabetes for ages 2+, and type 2 diabetes for ages 18+
- Freedom from tubes. Demonstrated clinical results without daily insulin injections1-2
- Waterproof3, on-body experience
- Now integrated with the Dexcom G6, the Dexcom G7, and the FreeStyle Libre 2 Plus Sensor
- The Omnipod 5 App for iPhone is integrated with Dexcom G7 and Dexcom G6. Compatible with iOS 17 and iOS 18, depending on your iPhone model.
- Simple to access through the pharmacy
For more information on how the Omnipod 5 algorithm works, you can watch the System Overview and Initiation, Everyday Use, and Expectation Setting videos.
Additional Training Resources
Omnipod 5 Video Tutorials - Pod Therapy Basics, What to Expect on Omnipod 5, and Omnipod 5 Product Training
General provider resources – User guides, Quick glance guides, Algorithm overview, iOS app resources
Settings Transfer Guide – current users
Managing Glucose Levels with Omnipod 5
Certified Pod Trainers (CPT)
Data Management
Data is crucial for clinical decision-making. Use Insulet-provided Glooko to view Omnipod 5 data.
- Insulet Provided Glooko resources, including report interpretation guides
- PantherTOOL for Omnipod 5
- A guide on helping patients get started with Glooko
Omnipod 5 Is Available Through the Pharmacy
"We now have 90% of covered lives.4 So, what that means: more than 300 million people in the United States can have access to Omnipod 5... We do that because Omnipod 5 is accessible through the pharmacy... for our users, it means they're not locked into a four year period through DME." - Dr. Trang Ly
Trang Ly, MBBS, FRACP, PhD is a senior VP and the Chief Medical Officer at Insulet®
Unlike other AIDs, Omnipod 5 is available through the pharmacy, which offers several benefits:
- Omnipod 5 is covered through Medicare Part D (not Part B) without the need for a C-peptide test
- Your patients can get started today*—more than half of covered Omnipod 5 scripts are filled within 24 hours through the pharmacy5
- The majority of Omnipod 5 patients pay $30 or less per month6
Other Resources
1. Renard E, et al. Efficacy and Safety of a Tubeless AID System
Compared With Pump Therapy With CGM in the Treatment of Type 1
Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel- Group Clinical Trial. Diabetes Care. 2024;47(12):2248-2257. doi:10.2337/dc24-1550.
2. Pasquel FJ, et al. JAMA Network Open
(2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70- 180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean HbA1c: ST vs. 13-week Omnipod 5: 8.2% vs. 7.4%, P<0.001.
3. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
4. Reflects coverage for Omnipod 5 DexG7G6 Intro Kit and Omnipod 5 DexG7G6 Pods in commercial channel only. Majority defined as >50%. Source: Managed Markets Insights & Technology, LLC. Data as of April 2025.
5. Majority defined as at least 50% of patient fill rate. Calculated based on the proportion of script fills within a 24-hour look forward period out of all script fills within a 90-day look forward period among all new to brand commercial, Medicare and Medicaid claims for the Omnipod 5 DexG7G6 Intro Kits from January 2024 to December 2024. Source: IQVIA PCL
6. Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library
INS-OHS-05-2025-00043 v2.0